



PHARMACEUTICAL 2018



Karyopharm Therapeutics Inc. Rank 178 of 342





PHARMACEUTICAL 2018



Karyopharm Therapeutics Inc. Rank 178 of 342

The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 81%, being 36% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	148,423
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	49,467
Liabilities, Non-Current	0
Other Assets	29,686
Other Compr. Net Income	57
Other Expenses	63
Other Liabilities	1,363
Other Net Income	3,222
Other Revenues	0
Property and Equipment	2,185
Research and Development	107,273
Selling, General and Administrative Expense	24,870

Output Variable	Value in 1000 USD
Assets	180,294
Liabilities	50,830
Expenses	132,206
Revenues	0
Stockholders Equity	129,464
Net Income	-128,984
Comprehensive Net Income	-128,956
Economic Capital Ratio	81%

